EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PTC Therapeutics's enterprise value is $2,435.4 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 was $-295.9 Mil. Therefore, PTC Therapeutics's EV-to-EBITDA for today is -8.23.
The historical rank and industry rank for PTC Therapeutics's EV-to-EBITDA or its related term are showing as below:
NAS:PTCT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.79 Med: -10.08 Max: 3.74
Current: -8.54
-96.79
-
3.74
During the past 10 years, the highest EV-to-EBITDA of PTC Therapeutics was 3.74. The lowest was -96.79. And the median was -10.08.
NAS:PTCT's EV-to-EBITDA is ranked lower than
99.99% of the 399
Companies
in the Biotechnology industry.
( Industry Median: 14.82
vs. NAS:PTCT: -8.54
)
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-01-26), PTC Therapeutics's stock price is $41.27.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $. Therefore, PTC Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PTC Therapeutics EV-to-EBITDA Historical Data
The historical data trend for PTC Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
EV-to-EBITDA
-1.86
-13.90
-18.58
-13.40
-13.65
PTC Therapeutics Quarterly Data
Dec16
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
EV-to-EBITDA
-8.46
-13.65
-11.10
-11.94
-7.76
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's EV-to-EBITDA falls into.
PTC Therapeutics EV-to-EBITDA Calculation
PTC Therapeutics's EV-to-EBITDA for today is calculated as:
PTC Therapeutics's current Enterprise Value is $2,435.4 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-295.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PTC Therapeutics's PE Ratio for today is calculated as:
PTC Therapeutics's share price for today is $41.27.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PTC Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
2.12(5.42%) Volume: 270,007 1:25PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
